NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
Clinical Trials
13 trialsNCT02836548 2025-07-10
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT05427617 2022-06-22
ACTDNAGLT
Hunan Cancer Hospital
Completed
NCT01583283 2022-02-23
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Celgene
Phase 1 Completed
NCT00792467 2021-05-11
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Italfarmaco
Phase 1/2 Completed
NCT00667082 2017-11-22
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase 1 Completed
NCT01460940 2017-11-14
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00719875 2017-03-03
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Yale University
Phase 1 Completed
NCT01580371 2016-10-06
CKD-581
Chong Kun Dang Pharmaceutical
Phase 1 Completed
NCT00185302 2015-12-14
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00738751 2015-02-04
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00005624 2012-09-25
CI-994 in Treating Patients With Advanced Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00697879 2011-11-28
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
Chroma Therapeutics
Phase 1 Completed